Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTX NASDAQ:DSGN NASDAQ:SCPH NASDAQ:TVRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$4.92+2.5%$4.43$3.39▼$16.00$53.28M0.7764,181 shs23,382 shsDSGNDesign Therapeutics$4.13+5.2%$3.77$2.60▼$7.77$234.63M1.56176,979 shs49,214 shsSCPHscPharmaceuticals$4.53+3.1%$3.68$1.94▼$5.65$238.73M0.38377,071 shs206,030 shsTVRDTvardi Therapeutics$23.28-10.8%$0.00$8.13▼$34.31$217.92M0.234,698 shs46,184 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics-2.04%-1.03%-0.83%+3.67%-60.82%DSGNDesign Therapeutics-2.00%+7.69%+2.08%+15.98%-12.50%SCPHscPharmaceuticals-2.01%+10.86%+11.14%+72.16%-7.19%TVRDTvardi Therapeutics-12.47%+19.50%+6.05%+2,610,999,900.00%+2,610,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTXAvalo Therapeutics3.1189 of 5 stars3.53.00.00.02.71.71.3DSGNDesign Therapeutics0.533 of 5 stars1.01.00.00.02.22.50.6SCPHscPharmaceuticals4.3756 of 5 stars3.54.00.04.22.71.70.6TVRDTvardi TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 3.00Buy$30.00509.76% UpsideDSGNDesign Therapeutics 2.00Hold$4.00-3.22% DownsideSCPHscPharmaceuticals 3.00Buy$14.00209.39% UpsideTVRDTvardi Therapeutics 3.00Buy$64.25175.99% UpsideCurrent Analyst Ratings BreakdownLatest AVTX, DSGN, TVRD, and SCPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025TVRDTvardi TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$62.007/11/2025TVRDTvardi TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$52.006/12/2025TVRDTvardi TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$78.006/2/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.005/21/2025TVRDTvardi TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$440K121.10N/AN/A$12.80 per share0.38DSGNDesign TherapeuticsN/AN/AN/AN/A$4.28 per shareN/ASCPHscPharmaceuticals$41.98M5.69N/AN/A$0.27 per share16.76TVRDTvardi TherapeuticsN/AN/AN/AN/A($3.02) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$35.13MN/A0.00N/AN/AN/A111.00%58.88%8/11/2025 (Estimated)DSGNDesign Therapeutics-$49.59M-$0.99N/AN/AN/AN/A-22.85%-22.02%8/4/2025 (Estimated)SCPHscPharmaceuticals-$85.15M-$1.91N/AN/AN/A-216.24%-594.07%-73.54%8/13/2025 (Estimated)TVRDTvardi Therapeutics-$70.87MN/A0.00∞N/A-595.39%-710.04%-79.00%N/ALatest AVTX, DSGN, TVRD, and SCPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SCPHscPharmaceuticals-$0.30N/AN/AN/A$15.41 millionN/A8/11/2025Q2 2025AVTXAvalo Therapeutics-$1.43N/AN/AN/AN/AN/A8/4/2025Q1 2025DSGNDesign Therapeutics-$0.32N/AN/AN/AN/AN/A5/14/2025Q1 2025DSGNDesign Therapeutics-$0.28-$0.31-$0.03-$0.31N/AN/A5/14/2025Q1 2025SCPHscPharmaceuticals-$0.28-$0.34-$0.06-$0.37$11.63 million$11.75 million5/12/2025Q1 2025AVTXAvalo Therapeutics-$1.07-$1.25-$0.18-$1.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ATVRDTvardi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A22.6122.61DSGNDesign TherapeuticsN/A28.3728.37SCPHscPharmaceuticals3.865.484.61TVRDTvardi TherapeuticsN/A32.4831.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%DSGNDesign Therapeutics56.64%SCPHscPharmaceuticals89.52%TVRDTvardi Therapeutics44.66%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics0.25%DSGNDesign Therapeutics31.20%SCPHscPharmaceuticals4.78%TVRDTvardi Therapeutics3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4010.83 million10.80 millionNot OptionableDSGNDesign Therapeutics4056.77 million39.06 millionOptionableSCPHscPharmaceuticals3052.79 million50.27 millionOptionableTVRDTvardi Therapeutics809.36 million9.07 millionN/AAVTX, DSGN, TVRD, and SCPH HeadlinesRecent News About These CompaniesRaymond James Initiates Coverage of Tvardi Therapeutics (TVRD) with Outperform RecommendationJuly 15 at 8:35 PM | msn.comTvardi Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 15 at 8:35 PM | finance.yahoo.comTvardi Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 15 at 8:00 AM | businesswire.comCantor Fitzgerald Predicts TVRD FY2025 EarningsJuly 15 at 2:47 AM | americanbankingnews.comTvardi Therapeutics (NASDAQ:TVRD) Earns Outperform Rating from Analysts at Raymond James FinancialJuly 14 at 9:31 AM | marketbeat.comTvardi Therapeutics (NASDAQ:TVRD) Research Coverage Started at Cantor FitzgeraldJuly 14 at 2:23 AM | americanbankingnews.comEquities Analysts Offer Predictions for TVRD FY2025 EarningsJuly 14 at 2:40 AM | marketbeat.comCantor Fitzgerald Initiates Coverage of Tvardi Therapeutics (TVRD) with Overweight RecommendationJuly 12, 2025 | msn.comTvardi Therapeutics (NASDAQ:TVRD) Earns Overweight Rating from Analysts at Cantor FitzgeraldJuly 11, 2025 | marketbeat.comTvardi Therapeutics (NASDAQ:TVRD) Stock Price Up 2.4% - What's Next?July 11, 2025 | marketbeat.comTvardi Therapeutics Inc News (TVRD) - Investing.comJune 27, 2025 | investing.comTVRD Tvardi Therapeutics, Inc.June 19, 2025 | seekingalpha.comPiper Sandler initiates Tvardi Therapeutics stock with overweight ratingJune 13, 2025 | uk.investing.comRecently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock UpsideJune 12, 2025 | benzinga.comTvardi Therapeutics Inc (TVRD)June 7, 2025 | investing.comTvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary FibrosisMay 27, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVTX, DSGN, TVRD, and SCPH Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$4.92 +0.12 (+2.50%) Closing price 03:59 PM EasternExtended Trading$4.92 0.00 (-0.10%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Design Therapeutics NASDAQ:DSGN$4.13 +0.20 (+5.17%) Closing price 03:59 PM EasternExtended Trading$4.16 +0.02 (+0.53%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.scPharmaceuticals NASDAQ:SCPH$4.53 +0.14 (+3.08%) Closing price 03:59 PM EasternExtended Trading$4.53 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.Tvardi Therapeutics NASDAQ:TVRD$23.28 -2.83 (-10.84%) As of 03:38 PM EasternCara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
